-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Clovis Oncology (NASDAQ:CLVS) Sees Large Growth in Short Interest
Clovis Oncology (NASDAQ:CLVS) Sees Large Growth in Short Interest
Clovis Oncology (NASDAQ:CLVS – Get Rating) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 33,160,000 shares, a growth of 14.4% from the August 31st total of 28,990,000 shares. Based on an average daily volume of 8,440,000 shares, the short-interest ratio is currently 3.9 days.
Hedge Funds Weigh In On Clovis Oncology
Large investors have recently bought and sold shares of the company. First Republic Investment Management Inc. bought a new position in Clovis Oncology in the first quarter valued at about $27,000. Mirabella Financial Services LLP acquired a new stake in shares of Clovis Oncology in the first quarter valued at about $36,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Clovis Oncology in the first quarter valued at about $40,000. Objective Capital Management LLC acquired a new stake in shares of Clovis Oncology in the second quarter valued at about $44,000. Finally, Bank of Montreal Can acquired a new stake in Clovis Oncology during the first quarter worth approximately $48,000. 29.47% of the stock is currently owned by institutional investors.
Get Clovis Oncology alerts:Clovis Oncology Trading Down 0.4 %
NASDAQ CLVS traded down $0.01 during trading on Tuesday, hitting $1.21. The stock had a trading volume of 8,464 shares, compared to its average volume of 4,165,091. Clovis Oncology has a 12 month low of $0.58 and a 12 month high of $4.76. The company's 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.53.
Clovis Oncology (NASDAQ:CLVS – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.09). During the same quarter in the previous year, the business earned ($0.61) earnings per share. As a group, analysts anticipate that Clovis Oncology will post -1.74 earnings per share for the current fiscal year.Clovis Oncology Company Profile
(Get Rating)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
See Also
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- 3 Safe Earnings Plays for a Risk-Off Market
- Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
- Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
- 3 Stocks Growing Their Businesses for 2023
- China-Based EV Maker BYD Set For Big European, Japanese Expansion
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
Clovis Oncology (NASDAQ:CLVS – Get Rating) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 33,160,000 shares, a growth of 14.4% from the August 31st total of 28,990,000 shares. Based on an average daily volume of 8,440,000 shares, the short-interest ratio is currently 3.9 days.
克洛维斯肿瘤学(纳斯达克:CLVS-GET评级)是空头股数9月份大幅增长的目标。截至9月15日,空头股数共有33,160,000股,较8月31日的28,99万股增长14.4%。以日均成交量8,440,000股计算,目前短息比率为3.9天。
Hedge Funds Weigh In On Clovis Oncology
对冲基金对克洛维斯肿瘤学的看法
Large investors have recently bought and sold shares of the company. First Republic Investment Management Inc. bought a new position in Clovis Oncology in the first quarter valued at about $27,000. Mirabella Financial Services LLP acquired a new stake in shares of Clovis Oncology in the first quarter valued at about $36,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Clovis Oncology in the first quarter valued at about $40,000. Objective Capital Management LLC acquired a new stake in shares of Clovis Oncology in the second quarter valued at about $44,000. Finally, Bank of Montreal Can acquired a new stake in Clovis Oncology during the first quarter worth approximately $48,000. 29.47% of the stock is currently owned by institutional investors.
大型投资者最近买卖了该公司的股票。First Republic Investment Management Inc.在第一季度购买了Clovis Oncology的一个新头寸,价值约为27,000美元。Mirabella Financial Services LLP在第一季度收购了Clovis Oncology的新股份,价值约3.6万美元。Sassicaia Capital Advisers LLC在第一季度收购了Clovis Oncology的新股份,价值约4万美元。目标资本管理有限责任公司在第二季度收购了Clovis Oncology的新股份,价值约44,000美元。最后,蒙特利尔银行可以在第一季度收购Clovis Oncology价值约4.8万美元的新股份。该公司29.47%的股票目前由机构投资者持有。
Clovis Oncology Trading Down 0.4 %
克洛维斯肿瘤学下跌0.4%
NASDAQ CLVS traded down $0.01 during trading on Tuesday, hitting $1.21. The stock had a trading volume of 8,464 shares, compared to its average volume of 4,165,091. Clovis Oncology has a 12 month low of $0.58 and a 12 month high of $4.76. The company's 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.53.
纳斯达克CLVS在周二的交易中下跌0.01美元,触及1.21美元。该股成交量为8,464股,而其平均成交量为4,165,091股。Clovis Oncology的12个月低点为0.58美元,12个月高位为4.76美元。该公司的50日移动均线价格为1.33美元,200日移动均线价格为1.53美元。
Clovis Oncology Company Profile
Clovis肿瘤学公司简介
(Get Rating)
(获取评级)
Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.
Clovis Oncology,Inc.是一家生物制药公司,专注于在美国、欧洲和国际上收购、开发抗癌药物并将其商业化。其商业产品包括Rubra(Rucaparib)片剂,这是一种小分子聚ADP-核糖聚合酶抑制剂,用于单一疗法治疗与恶性BRCA突变相关的晚期卵巢癌患者,这些患者已接受两种或两种以上化疗,并由FDA批准的Rubra辅助诊断选择进行治疗。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Clovis Oncology (CLVS)
- 3 Safe Earnings Plays for a Risk-Off Market
- Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
- Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
- 3 Stocks Growing Their Businesses for 2023
- China-Based EV Maker BYD Set For Big European, Japanese Expansion
- 免费获取StockNews.com关于克洛维斯肿瘤学(CLVS)的研究报告
- 避险市场的三大安全收益
- 泰森食品股价下跌,继续走低
- 小盘股Catalyst Pharma是市场上价格表现最好的公司之一
- 2023年3只股票实现业务增长
- 中国电动汽车制造商比亚迪将在欧洲和日本大举扩张
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受Clovis肿瘤学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Clovis Oncology和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧